Interactive Brokers Launches Redesigned IBKR Campus Website to Empower Investors Globally
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of its revamped IBKR Campus website, providing a comprehensive set of free educational resources to all levels of investors. IBKR Campus includes courses, webinars, podcasts, and market commentaries to help investors learn about trading, financial markets, and Interactive Brokers' trading tools.
The revamped IBKR Campus is simple to use, enabling investors to easily find what they are looking for. Beginning investors, as well as advanced traders, will find information to sharpen their skills and broaden their investment horizons. From free online courses on the concepts and tools of financial trading to lessons and quizzes on Interactive Brokers' trading tools, all investors can take advantage of these resources to become better investors. IBKR Campus also features commentaries from Steve Sosnick, Chief Strategist at Interactive Brokers, and José Torres, Senior Economist at Interactive Brokers, discussing themes impacting the markets and economy globally.
Steve Sanders, EVP of Marketing and Product Development at Interactive Brokers, emphasized the significance of education for IBKR, stating, "Education is at the heart of Interactive Brokers, and we firmly believe that knowledge is key to successful investing. With the user-friendly IBKR Campus site, we are empowering investors globally to stay informed about market events, improve their market understanding, and continuously develop their skills."
IBKR Campus services are available at no cost to both clients and non-clients globally. For the full suite of IBKR Campus resources, please see below and visit https://ibkrcampus.com/
Traders’ Academy: Investors can access free learning modules focused on IBKR’s trading tools at a pace that suits them. Newcomers can browse stock trading education, while more advanced students can take advantage of options trading education.
Traders’ Insight: Investors can review market-related articles, videos, and podcasts covering current financial market and economic events happening around the world. With market commentary from leading financial institutions, as well as from Interactive Brokers’ experts, daily insights explore catalysts impacting asset classes and markets worldwide.
IBKR Quant: Popular with computational finance students as well as those wanting to trade markets using computer power, articles are contributed by coders and developers in the quant space and seek to help programmers with concise and actionable code-based information.
IBKR Podcasts: Investors can listen to interviews and episodes with executives and researchers from prominent financial services companies examining topical themes impacting markets and trading including a recent podcast in which Steve Sosnick and José Torres assess the impact of monetary policy and recent economic data releases: Black Eye for Bond Bulls Gives Equity Traders a Headache
IBKR Webinars: Contributors explore market-related topics weekly, such as options trading, commodities, ETFs, volatility, and more.
Traders’ Glossary: Lets investors search for terms and definitions related to trading and investing, from products and order types to specific information about Interactive Brokers’ platforms, and offers suggestions for related terms and links.
Student Trading Lab: A free online resource for educators looking to blend finance or computer science classwork with real-world trading experiences. Students receive a paper trading account and can trade products across asset classes. The account equity fluctuates as if the trades were executed in the real market.
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities, and foreign exchange around the clock on over 150 markets in numerous countries and currencies, from a single unified platform to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. For the fifth consecutive year, Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its March 25, 2022, Best Online Brokers Review.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005260/en/
Contact information
Interactive Brokers Group, Inc. Media:
Katherine Ewert, media@ibkr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release
RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict
IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release
IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating
Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release
Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla
Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release
Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m
Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/ CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom